|
Novo Nordisk gives diabetics the tools to stick it to their disease. One of the world's leading producers of insulin, Novo Nordisk also makes insulin analogues, injection devices, and diabetes education materials. Its products include analogues Levemir and NovoRapid (which mimic natural insulin regulation more closely than human insulin) and the FlexPen, a pre-filled insulin injection tool. In addition to its diabetes portfolio, the firm has products in the areas of hemostasis management (blood clotting), human growth hormone, and hormone replacement therapy. The not-for-profit Novo Nordisk Foundation, through its Novo A/S subsidiary, controls the voting power in Novo Nordisk.
|
| | | Contact Information | |
Address: |
Novo Allé
2880 Bagsværd, Denmark
| | Phone: | +45-4444-8888 | | Fax: | +45-4449-0555 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 8627.70 M | | Revenue Growth (1 yr): | 4.50% | | Employees (2008): | 26,600 | | Employee Growth (1 yr): | 2.30% |
|
|
Key People
| | • |
President and CEO:
Lars Rebien Sørensen
| | • |
EVP and COO:
Kåre Schultz
| | • |
EVP and CFO:
Jesper Brandgaard
|
|
|
